🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 22/07/2009 | 33,96 | 34,50 | 33,58 | 34,05 | +0,06% | 2,71% | 1.115.400 |
| 21/07/2009 | 33,71 | 34,06 | 33,05 | 34,03 | +1,70% | 3,00% | 1.287.000 |
| 20/07/2009 | 33,33 | 33,93 | 32,95 | 33,46 | -0,21% | 2,94% | 1.145.200 |
| 17/07/2009 | 33,41 | 33,86 | 32,58 | 33,53 | +0,90% | 3,83% | 886.200 |
| 16/07/2009 | 32,89 | 33,73 | 32,83 | 33,23 | +0,76% | 2,74% | 1.455.300 |
| 15/07/2009 | 32,50 | 33,16 | 32,42 | 32,98 | +1,79% | 2,28% | 1.595.000 |
| 14/07/2009 | 32,84 | 33,08 | 32,34 | 32,40 | -1,79% | 2,25% | 1.396.200 |
| 13/07/2009 | 32,85 | 33,13 | 31,85 | 32,99 | +0,30% | 3,90% | 1.127.100 |
| 10/07/2009 | 33,14 | 33,56 | 32,39 | 32,89 | -1,50% | 3,53% | 1.050.900 |
| 09/07/2009 | 33,34 | 34,07 | 33,23 | 33,39 | -0,83% | 2,52% | 1.044.600 |
| 08/07/2009 | 33,40 | 34,03 | 33,29 | 33,67 | +1,81% | 2,22% | 1.632.000 |
| 07/07/2009 | 33,90 | 34,28 | 33,04 | 33,07 | -2,51% | 3,66% | 1.379.400 |
| 06/07/2009 | 33,71 | 34,49 | 33,61 | 33,92 | -0,09% | 2,61% | 1.287.000 |
| 02/07/2009 | 34,13 | 34,27 | 33,77 | 33,95 | -1,77% | 1,46% | 1.461.400 |
| 01/07/2009 | 35,61 | 35,93 | 34,42 | 34,56 | -3,92% | 4,24% | 1.812.900 |
| 30/06/2009 | 36,00 | 36,19 | 35,27 | 35,97 | -0,08% | 2,56% | 1.809.900 |
| 29/06/2009 | 35,89 | 36,30 | 35,11 | 36,00 | -0,11% | 3,32% | 2.382.900 |
| 26/06/2009 | 35,14 | 36,20 | 34,85 | 36,04 | +3,09% | 3,84% | 3.810.600 |
| 25/06/2009 | 33,66 | 35,00 | 33,31 | 34,96 | +2,79% | 5,02% | 1.785.000 |
| 24/06/2009 | 33,70 | 34,30 | 33,13 | 34,01 | +0,68% | 3,47% | 1.616.200 |
| 23/06/2009 | 33,09 | 34,02 | 32,78 | 33,78 | +2,02% | 3,75% | 2.652.700 |
| 22/06/2009 | 33,00 | 33,27 | 32,46 | 33,11 | -0,75% | 2,45% | 1.729.800 |
| 19/06/2009 | 33,14 | 33,64 | 32,96 | 33,36 | +1,80% | 2,05% | 2.163.100 |
| 18/06/2009 | 31,74 | 32,80 | 31,46 | 32,77 | +2,82% | 4,22% | 1.589.700 |
| 17/06/2009 | 30,68 | 32,30 | 30,68 | 31,87 | +3,78% | 5,28% | 1.720.800 |
| 16/06/2009 | 31,38 | 31,54 | 30,50 | 30,71 | -0,78% | 3,31% | 865.900 |
| 15/06/2009 | 31,40 | 31,40 | 30,69 | 30,95 | -1,84% | 2,26% | 1.337.300 |
| 12/06/2009 | 30,74 | 31,65 | 30,66 | 31,53 | +1,97% | 3,22% | 1.424.400 |
| 11/06/2009 | 30,14 | 31,08 | 30,14 | 30,92 | +2,62% | 3,12% | 1.592.900 |
| 10/06/2009 | 30,63 | 30,85 | 29,84 | 30,13 | -1,37% | 3,30% | 1.633.800 |